We learned that many cancer patients can tolerate a higher frequency of chemotherapy infusions than they typically get, and that with a higher frequency comes the high potential for better treatment outcomes. So we began to develop a personalized daily home blood test that will indicate when patients are ready for the next infusion ahead of the typical scheduling. Our optics-based test is non-invasive, detecting key informative blood cells through the skin without pain. A potentially transformative improvement in chemotherapy management. The key blood cells for our cancer application are also the key blood cells detected in acute infection. A simple test for these cells is sought throughout the resource poor regions of the world; especially where HIV-associated bacterial co-infection is endemic. There are approximately 4 billion people living in rural regions of our planet who currently have little or no access to testing for infection, which we've set out to provide. The project is completing its proof of principle phase and entering its first clinical studies with chemotherapy patients.

We learned that many cancer patients can tolerate a higher frequency of chemotherapy infusions than they typically get, and that with a higher frequency comes the high potential for better treatment outcomes. So we began to develop a personalized daily home blood test that will indicate when patients are ready for the next infusion ahead of the typical scheduling. Our optics-based test is non-invasive, detecting key informative blood cells through the skin without pain. A potentially transformative improvement in chemotherapy management. The key blood cells for our cancer application are also the key blood cells detected in acute infection. A simple test for these cells is sought throughout the resource poor regions of the world; especially where HIV-associated bacterial co-infection is endemic. There are approximately 4 billion people living in rural regions of our planet who currently have little or no access to testing for infection, which we've set out to provide. The project is completing its proof of principle phase and entering its first clinical studies with chemotherapy patients.

Vheda Health provides payers and health systems turnkey, digital health programs that deliver an 84% member compliance rate for high-risk populations. Through human touch and connected devices, our programs enable participants to overcome their social determinant and clinical barriers to compliance. Further, we streamline vendor management, enabling organizations to manage their entire population across chronic conditions, at scale. Vheda Health currently supports the following condition states: Asthma, COPD, Diabetes, Hypertension, Heart Failure, Maternity, Obesity, PERS, and Medication Adherence.

Vheda Health is a member compliance company dedicated to humanizing healthcare, through technology. Specializing in managing high-risk populations, our digital health programs deliver an average 84% member compliance rate through human touch and connected devices that enable participants to overcome their social determinant and clinical barriers. Our turnkey solution streamlines vendor management, enabling payers and health systems to manage populations across chronic conditions, at scale.